MedPath

Meropenem Pharmacokinetics in Spontaneous Bacterial Peritonitis

Conditions
Peritonitis Bacterial
Liver Cirrhosis
Interventions
Registration Number
NCT03571711
Lead Sponsor
Hannover Medical School
Brief Summary

The emergence of multidrug-resistant bacteria has increased the use of meropenem in spontaneous bacterial peritonitis (SBP). Additionally, recent studies suggested female gender as an independent risk factor for mortality in SBP. Studies regarding possible sex dependent differences in meropenem pharmacokinetics in SBP are scarce. The aim of this study is to determine the pharmacokinetics of meropenem during SBP in female and male patients with liver cirrhosis to investigate whether pharmacodynamics therapy goals are met.

Detailed Description

Spontaneous bacterial Peritonitis (SBP) in liver cirrhosis is a severe and increasingly common disease, which is associated with high morbidity, mortality and high costs for the investigator's health care system. In addition to age and severity of comorbidities, female sex is associated with detrimental outcome. Delayed diagnosis and therapy of SBP may lead to a higher mortality in this patient population. Therefore, an early diagnosis and adequate anti-infective therapy is essential. Due to the accumulation of antimicrobial-resistant (AMR) pathogens, especially in nosocomial SBP, empirical application of broad-spectrum antibiotics is recommended in the therapy of SBP.During the use of antibiotic drugs in general, pharmacokinetic/pharmacodynamic (PK/PD) targets, as the achieved time period over the minimal inhibitory concentration (MIC), should be evaluated to increase drug efficacy and reduce AMR development. Pharmacokinetic studies of meropenem concentrations at the infection site in this particular group of patients are rare in the literature. Recent studies in critically ill patients showed highly variable meropenem concentrations in peritoneal fluid after iv administration. The aim of this study is to determine the pharmacokinetics of meropenem during SBP in female and male patients with liver cirrhosis to investigate whether pharmacodynamics therapy goals are met.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
15
Inclusion Criteria
  • Age 18 - 75 years
  • Administration of meropenem
  • Diagnosis of liver cirrhosis
  • Diagnosis of spontaneous bacterial Peritonitis
  • Indication for peritoneal drainage catheter
Exclusion Criteria
  • Incapacity to give informed consent
  • Participation in other studies
  • Pregnancy

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Meropenem therapy in SBPMeropenem InjectionPatients in a tertiary care Hospital with meropenem injection due to spontaneous bacterial Peritonitis.
Primary Outcome Measures
NameTimeMethod
Trough concentrations of meropenem in single- and multiple-dose pharmacokinetics5 days

Single- and multiple-dose pharmacokinetic measurements of meropenem concentrations in blood plasma and ascites fluid and evaluation of trough concentrations.

Time over MIC of meropenem in single- and multiple-dose pharmacokinetics5 days

Single- and multiple-dose pharmacokinetic measurements of meropenem concentrations in blood plasma and ascites fluid and evaluation of achieved time period with drug concentration above the minimal inhibitory concentration breakpoint of 8 mg/L.

Peak concentrations of meropenem in single- and multiple-dose pharmacokinetics5 days

Single- and multiple-dose pharmacokinetic measurements of meropenem concentrations in blood plasma and ascites fluid and evaluation of Peak Levels concentrations in blood plasma and ascites fluid and evaluation of peak concentrations.

Area under the curve of meropenem in single- and multiple-dose pharmacokinetics5 days

Single- and multiple-dose pharmacokinetic measurements of meropenem concentrations in blood plasma and ascites fluid and evaluation of area under the curve characteristics

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

Hannover Medical School

🇩🇪

Hannover, Germany

© Copyright 2025. All Rights Reserved by MedPath